NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
KONAN GAKUEN (Japan)
Inventor
Iwasaki, Norimasa
Onodera, Tomohiro
Yamaguchi, Jun
Nagahama, Koji
Saito, Mitsuru
Abstract
It is desirable to provide a novel biomaterial and the like for tendon repair. Provided is a biomaterial for tendon repair containing a hydrogel formed by means of a cross-linking reaction between a reactive group A and a reactive group B, wherein the hydrogel contains a water-soluble polymer having the reactive group A, and mesenchymal stem cells having the reactive group B.
National Institute of Information and Communications Technology (Japan)
National University Corporation Hokkaido University (Japan)
Inventor
Fujiwara, Mikio
Takeoka, Masahiro
Sasaki, Masahide
Tomita, Akihisa
Abstract
A phase modulator calibration method includes steps of: providing a first delay interferometer to be used as a phase calibration reference and a second delay interferometer in which a phase modulator to be calibrated is installed in an optical path; for each of the first and second delay interferometers, measuring a delay time based on a time interval between pulses split from one input pulse and synchronizing the delay time with a cycle of a transmission clock; for the first delay interferometer, adjusting a phase difference so that input continuous-wave laser light produces an intensity-enhancing interference at an output; and determining the control signal with a calibration circuitry formed by connecting the first delay interferometer as a front stage and the second delay interferometer as a rear stage in a cascaded manner.
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour
G02F 1/21 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour by interference
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Terai, Kota
Utsuno, Futoshi
Higuchi, Hiroyuki
Tadanaga, Kiyoharu
Miura, Akira
Rosero Navarro, Nataly Carolina
Abstract
Provided is a sulfide solid electrolyte that has a novel crystal structure and exhibits an ionic conductivity, the sulfide solid electrolyte containing a lithium atom, a phosphorus atom, a sulfur atom, and at least one kind of halogen atom selected from a chlorine atom and a bromine atom, and having a specific diffraction peak in powdery X-ray diffractometry using CuKα line, and a method for producing a sulfide solid electrolyte, the method including mixing a solvent 1 having a heteroatom and a raw material 1 containing specific atoms to prepare a mixture, preparing a solution that contains a raw material 2 containing a halogen atom and a solvent 2 having a heteroatom, mixing the mixture and the solution to prepare a fluid, and heating the fluid.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Yoshida, Akihiro
Sonoki, Tomonori
Irwan, Kurnia
Guan, Guoqing
Abudula, Abuliti
Masuda, Takao
Yoshikawa, Takuya
Abstract
Provided are a lignin degradation catalyst that exhibits excellent lignin degradability and that is readily separated after degradation reaction, a method for producing the catalyst, and a method for degrading lignin. The lignin degradation catalyst according to the present invention contains a substrate and at least one metal compound immobilized on the substrate, wherein the at least one metal compound contains a copper compound. The method for producing a lignin degradation catalyst according to the present invention includes the step of brining a porous copper substrate into contact with a solution containing an oxidant to obtain a substrate having a copper compound immobilized thereon, or the step of subjecting a porous copper substrate to electro-oxidation to obtain a substrate having a copper compound immobilized thereon.
B01J 23/83 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with rare earths or actinides
B01J 23/94 - Regeneration or reactivation of catalysts comprising metals, oxides or hydroxides of the iron group metals or copper
B01J 35/56 - Foraminous structures having flow-through passages or channels, e.g. grids or three-dimensional monoliths
B01J 37/02 - Impregnation, coating or precipitation
B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves
C07C 45/32 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with molecular oxygen
C07C 51/21 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation with molecular oxygen
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Takayanagi, Taisuke
Yamada, Takahiro
Hirayama, Shusuke
Miyazaki, Koichi
Kobashi, Keiji
Aoyama, Hidefumi
Hashimoto, Takayuki
Katoh, Norio
Taguchi, Hiroshi
Yasuda, Koichi
Onodera, Yasuhito
Abstract
A treatment planning system is configured to create a treatment planning for radiotherapy and includes a processing device and a memory. The memory stores a plurality of calculation models, and the processing device uses at least two of the plurality of calculation models to calculate calculation values of biological effect indices representing an effect of radiotherapy with respect to a condition for radiotherapy, and searches for the condition so that at least two of the calculation values to be calculated approach a predetermined target value.
METHOD FOR DETECTING AMYLOID-ß BOUND TO BRAIN-NEURONALCELL-DERIVED EXOSOME IN BLOOD, KIT FOR DETECTION OF AMYLOID-ß BOUND TO BRAIN-NEURONAL-CELL-DERIVED EXOSOME IN BLOOD, AND METHOD FOR EVALUATING ACCUMULATION LEVEL OF AMYLOID-ß IN BRAIN
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Makino, Yoichi
Hirase, Takumi
Yuyama, Kohei
Abstract
There are provided a method for detecting amyloid-β bound to a brain-neuronal-cell-derived exosome in blood, the method including: a step of binding amyloid-β bound to the brain-neuronal-cell-derived exosome in blood to an amyloid-β-specific binding substance that specifically binds to amyloid-β, labeled with a nucleic acid fragment; and a step of detecting the amyloid-β-specific binding substance, and a method for evaluating an accumulation level of amyloid-β in a brain, the method including: a step of detecting amyloid-β bound to the brain-neuronal-cell-derived exosome in blood; and a step of evaluating an accumulation level of amyloid-β in a brain based on the detected amount of the amyloid-β.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
OSAKA UNIVERSITY (Japan)
NOF CORPORATION (Japan)
Inventor
Onoda, Akira
Hayashi, Takashi
Hamura, Ken
Suzuki, Akira
Kishida, Satoshi
Abstract
Polyoxyethylene derivatives represented by the following formula (1) provided by the present invention:
Polyoxyethylene derivatives represented by the following formula (1) provided by the present invention:
Polyoxyethylene derivatives represented by the following formula (1) provided by the present invention:
wherein the symbols in the formula are as defined in the specification, can form conjugates with polypeptide that can be degraded over a long time under physiological conditions to release the polypeptide.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Kamps, Landon Thomas
Nagata, Harunori
Hirai, Shota
Leung, Yownin Albert
Nobuhara, Yuki
Abstract
The present disclosure is directed to an ignition device including a housing, a bulk fuel, and at least two lead wires as electrodes. The bulk fuel is made of a plastic material, such as polylactic acid (PLA) or epoxy resin. The bulk fuel contains an internally dispersed powdery conductive material, thereby obtaining a conductive solid fuel. One end of the lead wire is partially embedded in the bulk fuel. The other end of the lead wire is connected to a power source. A portion of the bulk fuel is gasified by energizing the lead wire, and the gasified fuel is combusted by reaction with an oxidant.
F02K 9/95 - Rocket-engine plants, i.e. plants carrying both fuel and oxidant therefor; Control thereof characterised by starting or ignition means or arrangements
F02K 9/08 - Rocket-engine plants, i.e. plants carrying both fuel and oxidant therefor; Control thereof using solid propellants
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Sato, Yusuke
Sasaki, Kosuke
Harashima, Hideyoshi
Abstract
The present invention provides lipid nanoparticles that contain a pH-sensitive cationic lipid and a polyalkylene glycol-modified lipid. The pH-sensitive cationic lipid fraction of the total lipids that constitute the lipid nanoparticles is 10-25 mol %, the polyalkylene glycol-modified lipid fraction of the total lipids that constitute the lipid nanoparticles is 0.5-1.75 mol %, and the number average particle size of the lipid nanoparticles is at least 150 nm.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Yonezawa, Tetsu
Shirato, Hiroki
Miyamoto, Naoki
Abstract
A dispersion for an X-ray target in which gold nanoparticles and sodium alginate or a calcium phosphate-based bone reinforcing material are dispersed, in which the gold nanoparticles are in contact with the sodium alginate or the calcium phosphate-based bone reinforcing material.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Tasaka, Yuji
Yoshida, Taiki
Ohie, Kohei
Abstract
[Problem] To provide an ultrasonic physical properties measurement device that suppresses the generation of a secondary flow inside a cylinder, is more portable, and can suppress changes in physical properties.
[Problem] To provide an ultrasonic physical properties measurement device that suppresses the generation of a secondary flow inside a cylinder, is more portable, and can suppress changes in physical properties.
[Solution] An ultrasonic physical properties measurement device 1 that: uses ultrasonic waves to measure the flow velocity profile of fluids that flow inside a cylinder 2, by rotating the cylinder 2 backwards and forwards in a fixed cycle; and calculates the physical properties of fluid from the flow velocity profile. The cylinder 2: has an upper end surface 21 and lower end surface 22 that are penetrated such that fluid can flow therethrough; and comprises a rotation mechanism 3 that supports all or part of the cylinder 2 in a state of immersion in the fluid and rotates the cylinder 2 backwards and forwards.
G01F 1/66 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by measuring frequency, phase shift or propagation time of electromagnetic or other waves, e.g. using ultrasonic flowmeters
12.
CELL MASS-FORMING MEMBER, CULTURE VESSEL, METHOD FOR PRODUCING CULTURED CELLS, AND CULTURED CELLS WITH CELL MASS-FORMING MEMBER
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Oji Holdings Corporation (Japan)
Inventor
Miyatake, Yukiko
Shigetomi, Kaori
Tokuno, Hisako
Dai, Kotaro
Shinotsuka, Kei
Abstract
A cell mass-forming member that is capable of easily forming a cell mass and superior in industrial mass productivity; a culture container equipped with the cell mass-forming member; a method for producing cultured cells using the cell mass-forming member; and cultured cells with a cell mass-forming member that are equipped with the cell mass-forming member. The cell mass-forming member has a base material, an adhesion inhibition area and a cell adhesion area are formed on the surface of the base material; a micro-concavo-convex structure area including a plurality of convex portions is formed in the cell adhesion area; and a hydrophilic coating layer is formed on both the adhesion inhibition area and the cell adhesion area. The culture container and the cultured cells with a cell mass-forming member are equipped with the cell mass-forming member. The method for producing cultured cells includes using the cell mass-forming member.
NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION (Japan)
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Nippon Soda Co., Ltd. (Japan)
Inventor
Kushida, Atsuhiko
Sakata, Itaru
Tanino, Keiji
Kato, Kousuke
Itabashi, Takuya
Kanazawa, Jun
Ikeda, Yuto
Kitayama, Takashi
Koizumi, Satoshi
Osawa, Yoko
Inoue, Tsutomu
Abstract
An object of the present invention is to provide an industrially easily available hatching factor on Globodera pallida larvae, a control agent and a control method using the same. The Globodera pallida control agent of the present invention contains, as an active ingredient, at least one selected from a compound of formula (I) below, a stereoisomer thereof, and a salt thereof [wherein Ar represents a substituted or unsubstituted phenyl group or the like; R1 each independently represents a group such as a substituted or unsubstituted C1 to 6 alkyl group and a substituted or unsubstituted C2 to 6 alkenyl group; R2 represents a hydrogen atom or a substituted or unsubstituted C1 to 6 alkyl group; the partial structure —Y—X— represents a group represented by *—N(Rb)—C(═X1)—**; X1 each independently represents an oxygen atom or a sulfur atom; Rb represents hydrogen atom or the like; where * indicates a binding position to the carbon atom having two R1, and ** indicates a binding position to Z; and Z represents a substituted or unsubstituted methylene group, or a substituted or unsubstituted dimethylene group.]
An object of the present invention is to provide an industrially easily available hatching factor on Globodera pallida larvae, a control agent and a control method using the same. The Globodera pallida control agent of the present invention contains, as an active ingredient, at least one selected from a compound of formula (I) below, a stereoisomer thereof, and a salt thereof [wherein Ar represents a substituted or unsubstituted phenyl group or the like; R1 each independently represents a group such as a substituted or unsubstituted C1 to 6 alkyl group and a substituted or unsubstituted C2 to 6 alkenyl group; R2 represents a hydrogen atom or a substituted or unsubstituted C1 to 6 alkyl group; the partial structure —Y—X— represents a group represented by *—N(Rb)—C(═X1)—**; X1 each independently represents an oxygen atom or a sulfur atom; Rb represents hydrogen atom or the like; where * indicates a binding position to the carbon atom having two R1, and ** indicates a binding position to Z; and Z represents a substituted or unsubstituted methylene group, or a substituted or unsubstituted dimethylene group.]
A01N 43/18 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with sulfur as the ring hetero atom
A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
A01N 43/10 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with sulfur as the ring hetero atom
A01N 43/36 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
CATALYST STRUCTURE FOR SYNTHESIS GAS PRODUCTION, SYNTHESIS GAS PRODUCTION DEVICE, AND METHOD FOR PRODUCING CATALYST STRUCTURE FOR SYNTHESIS GAS PRODUCTION
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Banba, Yuichiro
Fukushima, Masayuki
Kawamata, Yuki
Iwano, Yuki
Mori, Tomohiko
Fujikawa, Takashi
Masuda, Takao
Nakasaka, Yuta
Yoshikawa, Takuya
Abstract
A catalyst structure for synthesis gas production is used to produce a synthesis gas that includes carbon monoxide and hydrogen. The structure includes a carrier with a porous structure that comprises a zeolite-type compound; first catalyst particles that contain at least one iron-group element selected from the group consisting of nickel, iron, and cobalt; and a second catalyst that contains at least one transition metal element with redox capacity. The carrier includes, inside thereof, mutually communicating passages; the first catalyst particles are present at least in the passages of the carrier; and the second catalyst is present at least in the interior or on an outer surface of the carrier.
B01J 37/02 - Impregnation, coating or precipitation
B01J 37/10 - Heat treatment in the presence of water, e.g. steam
C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Furusawa, Koichiro
Takahashi, Kazuyuki
Murata, Naoki
Matsushima, Hisayoshi
Nago, Toranosuke
Abstract
An object of the present invention is to provide a separation system and a separation method that can separate deuterium from a fluid containing light hydrogen and deuterium with high separation efficiency while suppressing equipment deterioration. The present invention provides a separation system including a plurality of separation devices connected in series; each of the plurality of separation devices includes an electrolyte membrane to which an anode catalyst layer and a cathode catalyst layer are provided; a first inflow passage through which a first fluid containing light hydrogen and deuterium flows in, and a first outflow passage through which a second fluid having a lower deuterium content than that of the first fluid flows out are connected to an anode flow passage, a second inflow passage through which a third fluid flows into and a second outflow passage through which a fourth fluid containing light water and heavy water flows out are connected to a cathode flow passage; at least a separation device provided at the most upstream side among the plurality of separation devices is a first separation device into which a gas containing water vapor flows as a third fluid, and from which the third fluid and deuterium that has moved from the anode catalyst layer into the cathode catalyst layer are discharged as the fourth fluid.
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
C25B 9/70 - Assemblies comprising two or more cells
16.
METHOD FOR PRODUCING LAYERED COMPOSITE METAL OXIDE CRYSTAL MATERIAL
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Matsui, Masaki
Maeda, Rannosuke
Abstract
The objective of the present invention is to provide a method for producing a layered composite metal oxide crystal material, which can be utilized as a positive electrode material for a lithium ion secondary battery or the like, in a milder condition, and methods for producing a positive electrode and a lithium ion secondary battery using the above method. The method for producing a layered composite metal oxide crystal material according to the present invention, wherein the layered composite metal oxide crystal material comprises a composite metal oxide represented by the formula: LixMOy wherein M is 1 or 2 or more of transition metals, and a part of the M may be substituted with Al and/or Mg, x is the number of 1 or more and 2 or less, y is the number of 2 or more and 3 or less, a value of x+n is 2×y, wherein n is an average valence of the transition metal M, is characterized in comprising the step of calcining a mixture comprising a monovalent anion salt of lithium, a monovalent anion salt of sodium and/or potassium, and a monovalent anion salt of the transition metal at 150° C. or higher and 400° C. or lower in the presence of a water molecule and oxygen.
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
H01M 10/0587 - Construction or manufacture of accumulators having only wound construction elements, i.e. wound positive electrodes, wound negative electrodes and wound separators
17.
COMPOUND, MANUFACTURING METHOD THEREFOR, ANTIMICROBIAL AGENT, AND MEDICINAL DRUG
National University Corporation Hokkaido University (Japan)
Inventor
Takata, Masachika
Sunahara, Hirofumi
Wakimoto, Toshiyuki
Matsuda, Kenichi
Abstract
A compound represented by Formula (1), Formula (2), or Formula (3), or a salt thereof, or a solvate thereof:
A compound represented by Formula (1), Formula (2), or Formula (3), or a salt thereof, or a solvate thereof:
wherein R1, R2, and R3 are the same or different and each represent a hydrazine group, an N-hydroxy-acetylamino group, or an N-hydroxy-formylamino group.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Amakawa, Ayaka
Sano, Maki
Hatanaka, Hokkaido
Hatanaka, Yutaka
Abstract
A slide number estimation apparatus (2000) acquires a slide image (30). The slide image (30) an image of a specimen slide (20) obtained from a tissue piece (10) of a subject. The slide number estimation apparatus (2000) estimates the number of tumor cells included in a region of interest (22) of the specimen slide (20) corresponding to the obtained slide image (30) using the slide image (30). The slide number estimation apparatus (2000) estimates the number of the specimen slides (20) to be obtained from the tissue piece (10) for conducting a predetermined test based on the estimated number of tumor cells.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Shionogi & Co., Ltd. (Japan)
Inventor
Kitajima, Masaaki
Iwamoto, Ryo
Masago, Yusaku
Hayase, Shin
Katayama Adachi, Yuka
Abstract
The present invention provides a method for quantitatively detecting virus-derived RNA and/or DNA in an environmental sample or a fecal sample with high sensitivity, and a kit for quantitatively detecting virus-derived RNA and/or DNA in an environmental sample or a fecal sample with high sensitivity.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
20.
COPPER CHELATOR, ANTICANCER AGENT AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR WILSON'S DISEASE
National University Corporation Hokkaido University (Japan)
Inventor
Takata, Masachika
Sunahara, Hirofumi
Wakimoto, Toshiyuki
Matsuda, Kenichi
Abstract
A copper chelating agent that contains at least one compound selected from the group consisting of a compound represented by Formula (1), a compound represented by Formula (2), a compound represented by Formula (3), a compound represented by Formula (4), a salt thereof, and a solvate thereof:
A copper chelating agent that contains at least one compound selected from the group consisting of a compound represented by Formula (1), a compound represented by Formula (2), a compound represented by Formula (3), a compound represented by Formula (4), a salt thereof, and a solvate thereof:
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Maenaka, Katsumi
Matsuda, Akira
Sawa, Hirofumi
Orba, Yasuko
Sasaki, Michihito
Uemura, Kentaro
Abstract
[Problem] The present invention has as an object to provide an antiviral agent effective as a remedy for COVID-1 9 and other viral infections.
[Problem] The present invention has as an object to provide an antiviral agent effective as a remedy for COVID-1 9 and other viral infections.
[Resolution Means] Provided is an antiviral agent and the like, made of: the compound represented by general formula (1) or (2) below [R1 being —(CH2)n1—Z1—R11 2 r —CH—(—Z1—R11,)(n1 being 0 or 1; Z1 being a single bond, —O—, —NH—, —S—, —SO—, —SO2—,SO—CO—, —CO—O—, or —CH═N—O—; R11 being a hydrogen atom, an alkyl group having 1 to 6 carbons, —NR12 R13, —N3,—NO2,—CN, —CH2—CO—O—R14, or a five- or six-membered heterocyclic group including a nitrogen atom; R12 and R13 each independently being a hydrogen atom or an alkyl group having 1 to 6 carbons; and R14 being a hydrogen atom or an alkyl group having 1 to 6 carbons], a derivative thereof, a salt of these compounds, or a solvate thereof.
[Problem] The present invention has as an object to provide an antiviral agent effective as a remedy for COVID-1 9 and other viral infections.
[Resolution Means] Provided is an antiviral agent and the like, made of: the compound represented by general formula (1) or (2) below [R1 being —(CH2)n1—Z1—R11 2 r —CH—(—Z1—R11,)(n1 being 0 or 1; Z1 being a single bond, —O—, —NH—, —S—, —SO—, —SO2—,SO—CO—, —CO—O—, or —CH═N—O—; R11 being a hydrogen atom, an alkyl group having 1 to 6 carbons, —NR12 R13, —N3,—NO2,—CN, —CH2—CO—O—R14, or a five- or six-membered heterocyclic group including a nitrogen atom; R12 and R13 each independently being a hydrogen atom or an alkyl group having 1 to 6 carbons; and R14 being a hydrogen atom or an alkyl group having 1 to 6 carbons], a derivative thereof, a salt of these compounds, or a solvate thereof.
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
National University Corporation Hokkaido University (Japan)
PuREC Co., Ltd. (Japan)
Mochida Pharmaceutical Co., Ltd. (Japan)
Inventor
Sudo, Hideki
Ukeba, Daisuke
Yamada, Katsuhisa
Ura, Katsuro
Suzuki, Hisataka
Iyoku, Yumi
Suyama, Takashi
Abstract
Provided is a composition for promotion of the regeneration of the nucleus pulposus of an intervertebral disc, said composition comprising a low endotoxin monovalent metal salt of alginic acid and mesenchymal stem cells. In particular, the composition of the present invention promotes the regeneration of the nucleus pulposus of an intervertebral disc via activation of nucleus pulposus cells by human bone marrow-derived high-purity mesenchymal stem cells and/or differentiation of human bone marrow-derived high-purity mesenchymal stem cells into nucleus pulposus cells.
NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY (Japan)
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
THE UNIVERSITY OF TOKYO (Japan)
Inventor
Yoshino, Ken-Ichiro
Fujiwara, Mikio
Tomita, Akihisa
Koashi, Masato
Takeoka, Masahiro
Sasaki, Masahide
Abstract
An object is to prevent eavesdropping in quantum key distribution. A decoding unit decodes a quantum signal incident thereinto. A plurality of detect photons of the decoded quantum signal output from the decoding unit. A signal processing unit detects bits of the decoded quantum signal based on photon detection results of the plurality of detectors. A control unit perform switching processing by switching destinations to which two decoded quantum signals corresponding to one encoding basis are output between the plurality of detectors, and switching the bits detected by the signal processing unit based on the respective photon detection results of the plurality of detectors.
TOKYO METROPOLITAN PUBLIC UNIVERSITY CORPORATION (Japan)
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Kakehi, Koji
Hayashi, Shigenari
Kuo, Yen-Ling
Abstract
A heat-resistant alloy contains Y, a content of Ni is a content of Ni is 58.0 mass % or greater, a content of Cr is 20.0 mass % or greater and 23.0 mass % or less, a content of Mo is 8.0 mass % or greater and 10.0 mass % or less, a content of Nb is 3.15 mass % or greater and 4.15 mass % or less, a content of O is 0.002 mass % or greater and 0.1 mass % or less, and a ratio of a content of Y in terms of mass to a content of O in terms of mass is 0.5 or greater and 100 or less.
C22C 1/04 - Making non-ferrous alloys by powder metallurgy
B22F 1/00 - Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
B33Y 70/00 - Materials specially adapted for additive manufacturing
C22C 19/05 - Alloys based on nickel or cobalt based on nickel with chromium
C22F 1/10 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of nickel or cobalt or alloys based thereon
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Nakamura, Takashi
Harashima, Hideyoshi
Sato, Yusuke
Yamada, Koharu
Nakade, Taisei
Abstract
The present invention provides a lipid nanoparticle and the like containing a pH-sensitive cationic lipid represented by formula (1) (in formula (1), R1 and R2 are each independently a straight-chain C10-14 alkyl group, a straight-chain C10-20 alkenyl group having one or two unsaturated bonds, or —CH(R5)(R6)(where R5 and R6 are each independently a straight-chain C5-10 alkyl group); p represents an integer of 3-8; and R3 and R4 are each independently a methyl group or an ethyl group].
The present invention provides a lipid nanoparticle and the like containing a pH-sensitive cationic lipid represented by formula (1) (in formula (1), R1 and R2 are each independently a straight-chain C10-14 alkyl group, a straight-chain C10-20 alkenyl group having one or two unsaturated bonds, or —CH(R5)(R6)(where R5 and R6 are each independently a straight-chain C5-10 alkyl group); p represents an integer of 3-8; and R3 and R4 are each independently a methyl group or an ethyl group].
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
National University Corporation Hokkaido University (Japan)
Inventor
Matsuda, Tadashi
Oritani, Kenji
Kitai, Yuichi
Abstract
The present invention provides a peptide that consists of an amino acid sequence with 20 or fewer residues containing at least one amino acid sequence selected from the group consisting of the amino acid sequence represented in SEQ ID NO: 1, the amino acid sequence represented in SEQ ID NO: 2 and the amino acid sequence represented in SEQ ID NO: 38, the peptide having an activity to inhibit proliferation of a tumor cell or having an activity to inhibit binding between an epidermal growth factor receptor and a signal-transducing adaptor family member-2 (STAP-2); a peptide with a cell-penetrating peptide added to a terminus of the above peptide with or without a linker sequence interposed between the cell-penetrating peptide and the terminus; and pharmaceutical compositions containing any of these peptides.
National University Corporation Hokkaido University (Japan)
Inventor
Kawaguchi, Yuki
Shoji, Hiroyuki
Orikawa, Koji
Ogasawara, Satoshi
Murakami, Naoki
Abstract
A printed board coil forms a coil with a plurality of turns, each formed by stacking a first layer having a first winding pattern and a second layer having a second winding pattern while having an insulation layer intervening therebetween. The first layers and the second layers are used for forming each of the coils. The coils are stacked having each of the insulation layers intervening between the coils by arranging the first layer and the second layer alternately in the stacking direction of the respective layers. The coils are connected in parallel to one another.
National University Corporation Hokkaido University (Japan)
Nitto Denko Corporation (Japan)
Inventor
Sato, Yusuke
Harashima, Hideyoshi
Hashiba, Kazuki
Taguchi, Masamitsu
Sakamoto, Sachiko
Shishido, Takuya
Otsu, Ayaka
Maeda, Yoshiki
Abstract
The present invention addresses the problem of providing lipid nanoparticles which function as gene transfer carriers capable of selective transfer to the liver or spleen. Lipid nanoparticles which contain a pH-sensitive cationic lipid represented by formula (I) [a represents an integer of 3-5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (R11 and R12 each independently represent a linear or branched C2-15 alkyl group; c represents 0 or 1; v represents an integer of 4-12); and X represents a group represented by general formula (B)(d represents an integer of 0-3; and R3 and R4 each independently represent a C1-4 alkyl group or C2-4 alkenyl group, while R3 and R4 may form a 5- to 7-membered non-aromatic heterocycle) or represents a 5- to 7-membered non-aromatic heterocyclic group]. (I) (R1)(R2)C(OH)—(CH2)a—(O—CO)b—X. (A): (R11)(R12)—CH—(CO—O)c—(CH2)v-. (B):—(CH2)d-N(R3)(R4).
The present invention addresses the problem of providing lipid nanoparticles which function as gene transfer carriers capable of selective transfer to the liver or spleen. Lipid nanoparticles which contain a pH-sensitive cationic lipid represented by formula (I) [a represents an integer of 3-5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (R11 and R12 each independently represent a linear or branched C2-15 alkyl group; c represents 0 or 1; v represents an integer of 4-12); and X represents a group represented by general formula (B)(d represents an integer of 0-3; and R3 and R4 each independently represent a C1-4 alkyl group or C2-4 alkenyl group, while R3 and R4 may form a 5- to 7-membered non-aromatic heterocycle) or represents a 5- to 7-membered non-aromatic heterocyclic group]. (I) (R1)(R2)C(OH)—(CH2)a—(O—CO)b—X. (A): (R11)(R12)—CH—(CO—O)c—(CH2)v-. (B):—(CH2)d-N(R3)(R4).
(R1)(R2)C(OH)—(CH2)a—(O—CO)b—X (I)
The present invention addresses the problem of providing lipid nanoparticles which function as gene transfer carriers capable of selective transfer to the liver or spleen. Lipid nanoparticles which contain a pH-sensitive cationic lipid represented by formula (I) [a represents an integer of 3-5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (R11 and R12 each independently represent a linear or branched C2-15 alkyl group; c represents 0 or 1; v represents an integer of 4-12); and X represents a group represented by general formula (B)(d represents an integer of 0-3; and R3 and R4 each independently represent a C1-4 alkyl group or C2-4 alkenyl group, while R3 and R4 may form a 5- to 7-membered non-aromatic heterocycle) or represents a 5- to 7-membered non-aromatic heterocyclic group]. (I) (R1)(R2)C(OH)—(CH2)a—(O—CO)b—X. (A): (R11)(R12)—CH—(CO—O)c—(CH2)v-. (B):—(CH2)d-N(R3)(R4).
(R1)(R2)C(OH)—(CH2)a—(O—CO)b—X (I)
(R11)(R12)—CH—(CO—O)c—(CH2)v- (A)
The present invention addresses the problem of providing lipid nanoparticles which function as gene transfer carriers capable of selective transfer to the liver or spleen. Lipid nanoparticles which contain a pH-sensitive cationic lipid represented by formula (I) [a represents an integer of 3-5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (R11 and R12 each independently represent a linear or branched C2-15 alkyl group; c represents 0 or 1; v represents an integer of 4-12); and X represents a group represented by general formula (B)(d represents an integer of 0-3; and R3 and R4 each independently represent a C1-4 alkyl group or C2-4 alkenyl group, while R3 and R4 may form a 5- to 7-membered non-aromatic heterocycle) or represents a 5- to 7-membered non-aromatic heterocyclic group]. (I) (R1)(R2)C(OH)—(CH2)a—(O—CO)b—X. (A): (R11)(R12)—CH—(CO—O)c—(CH2)v-. (B):—(CH2)d-N(R3)(R4).
(R1)(R2)C(OH)—(CH2)a—(O—CO)b—X (I)
(R11)(R12)—CH—(CO—O)c—(CH2)v- (A)
—(CH2)d—N(R3)(R4) (B)
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Tanaka, Shinya
Yasuda, Kazunori
Gong, Jian Ping
Tsuda, Masumi
Kurokawa, Takayuki
Abstract
The present invention relates to a method of producing cancer stem cells that comprises culturing a living cell population containing cancer cells in the presence of a gel substance to obtain a living cell population containing cancer stem cells, wherein the gel substance is a material that induces expression of osteopontin in at least a portion of cells contained in the living cell population. Moreover, the present invention relates to an agent for inducing conversion of cancer cells to cancer stem cells that comprises a gel substance that induces expression of osteopontin in at least a portion of the cells contained in a living cell population. The gel substance is a synthetic polymer gel composed of, for example, double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel. The present invention provides means and a method that enable the preparation of cancer stem cells in a relatively short period of time and at a relatively low culturing cost without requiring expensive equipment.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Yamazaki, Kumiko
Kano, Shuto
Masubuchi, Yuji
Kikkawa, Shinichi
Abstract
A dielectric composition comprises a crystal of an oxynitride. A peak attributed to absence of a center of symmetry of the crystal of the oxynitride is detected by Raman spectroscopy of the dielectric composition within a Raman shift range of 500 cm−1 or less.
C23C 16/30 - Deposition of compounds, mixtures or solid solutions, e.g. borides, carbides, nitrides
B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
C23C 16/515 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating using electric discharges using pulsed discharges
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Kodama, Yuki
Kuwatani, Masaki
Hirata, Hajime
Ogawa, Mikako
Nakajima, Kohei
Abstract
A light irradiation device includes a tube including a tube main body and a light emitting portion, a plurality of wiring boards disposed inside the light emitting portion and including a plurality of light emitting elements disposed at an equal interval mounted, an anode lead wire for connecting an anode terminal of each of the wiring boards to a power source, and a cathode lead wire for connecting a cathode terminal of each of the wiring boards to the power source. In the light emitting portion, a central lumen and surrounding lumens that are arrayed at a 90° interval around the central lumen are formed. The wiring boards are disposed in the respective surrounding lumens with the light emitting elements arrayed along a longitudinal direction of the light emitting portion.
National University Corporation Hokkaido University (Japan)
SYSMEX CORPORATION (Japan)
Inventor
Kinjo, Masataka
Ganguly, Akshay
Ramaswamy, Lausonia
Abstract
Disclosed is a method for obtaining information on von Willebrand factor (VWF), comprising the following steps: denaturing, with urea, VWF contained in a biological sample; fluorescently labeling the denatured VWF using a capturing agent that comprises a fluorescent substance and binds to the denatured VWF; and obtaining information on the size of the fluorescently-labeled VWF by fluorescence correlation spectroscopy or fluorescence cross-correlation spectroscopy.
National University Corporation Hokkaido University (Japan)
Inventor
Sato, Masahiro
Nakashima, Takumi
Ishii, Kazuei
Ochiai, Satoru
Abstract
The present invention provides a method of culturing an alga that enables practical realization of low-cost and space-saving production of biofuels and bioenergy by culturing the alga using a reaction tank equipped with a digestive solution tank comprising digestive solution containing high concentration of nutrient salts, a membrane with a pore size of 0.45 µm or less and a culture tank comprising culture solution and the alga, which comprises consuming the nutrient salts by the alga in the culture tank to maintain the difference in concentration the nutrient salts between the digestive solution tank and the culture tank and supplying the nutrient salts contained in the digestive solution through the membrane into the culture solution by the diffusion depending on the concentration difference as well as an alga culture system therefor.
C12N 1/12 - Unicellular algae; Culture media therefor
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
FURUKAWA ELECTRIC CO., LTD. (Japan)
Inventor
Masuda, Takao
Nakasaka, Yuta
Yoshikawa, Takuya
Kato, Sadahiro
Fukushima, Masayuki
Inamori, Kojiro
Takahashi, Hiroko
Banba, Yuichiro
Sekine, Kaori
Abstract
A method for making a functional structural body includes a skeletal body of a porous structure composed of a zeolite-type compound, and at least one type of metallic nanoparticles present in the skeletal body, the skeletal body having channels connecting with each other, the metallic nanoparticles being present at least in the channels of the skeletal body.
B01J 29/16 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the faujasite type, e.g. type X or Y containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
B01J 29/18 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the mordenite type
B01J 29/08 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the faujasite type, e.g. type X or Y
B01J 29/20 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the mordenite type containing iron group metals, noble metals or copper
B01J 29/10 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the faujasite type, e.g. type X or Y containing iron group metals, noble metals or copper
B01J 29/61 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the type L containing iron group metals, noble metals or copper
B01J 29/26 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the mordenite type containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
B01J 29/42 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11 containing iron group metals, noble metals or copper
B01J 29/40 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11
B01J 29/69 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the ferrierite type, e.g. types ZSM-21, ZSM-35 or ZSM-38 containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
B01J 29/70 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of types characterised by their specific structure not provided for in groups
B01J 29/65 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the ferrierite type, e.g. types ZSM-21, ZSM-35 or ZSM-38
B01J 29/66 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the ferrierite type, e.g. types ZSM-21, ZSM-35 or ZSM-38 containing iron group metals, noble metals or copper
B01J 29/64 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the type L containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
B01J 29/78 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of types characterised by their specific structure not provided for in groups containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
B01J 29/72 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of types characterised by their specific structure not provided for in groups containing iron group metals, noble metals or copper
C01B 39/02 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
B01D 53/94 - Chemical or biological purification of waste gases of engine exhaust gases by catalytic processes
35.
METHOD FOR DIAGNOSING NONALCOHOLIC STEATOHEPATITIS
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Sakurai, Toshihiro
Hui, Shu-Ping
Chiba, Hitoshi
Abstract
A problem of the present invention is to provide a diagnostic biomarker of nonalcoholic steatohepatitis (NASH) useful for differentiation of simple steatosis (SS) from NASH and use thereof. Specifically, the present invention relates to a diagnostic biomarker of nonalcoholic steatohepatitis used to differentiate nonalcoholic steatohepatitis from simple steatosis comprising the oxidized apolipoprotein A-I (ApoA-I) modified by dioxidation of the 72nd tryptophan in the ApoA-I consisting of the amino acid sequence as shown in SEQ ID NO: 1.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Yamaguchi, Koji
Ogasawara, Satoshi
Ohara, Shunsuke
Abstract
A common mode filter circuit comprises a common mode transformer unit, an inverter, and a capacitor unit. Each of the first common mode transformer, the second common mode transformer, and the third common mode transformer comprises a first secondary wound wire, a second secondary wound wire, a third secondary wound wire, and a primary wound wire. A ratio of a number of turns of the primary wound wire to a number of turns of the first secondary wound wire, a ratio of a number of turns of the primary wound wire to a number of turns of the second secondary wound wire, and a ratio of a number of turns of the primary wound wire to a number of turns of the third secondary wound wire are each 3:1 in each of the first common mode transformer, the second common mode transformer, and the third common mode transformer.
CELL CULTURE SUBSTRATE, CANCER CELL AGGREGATE AND METHOD FOR MANUFACTURING SAME USING SAID SUBSTRATE, AND DRUG SCREENING METHOD USING SAID CANCER CELL AGGREGATE
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Miyatake, Yukiko
Shigetomi, Kaori
Okajima, Takaharu
Kasahara, Masanori
Abstract
A method for producing a cancer cell aggregate having certain properties, screening a drug for preventing and/or treating cancer, and determining anoikis resistance in epithelial cancer cells. The method includes culturing cells using a cell culture substrate having a base material and a biocompatible polymer layer. The cell culture substrate has rough sections not covered with the biocompatible polymer layer on the surface of the cell culture substrate. Each of the rough sections has a shape of a spot with a diameter of 20-100 μm, or a groove with a width of 3-30 μm with an end part of the rough section being optionally connected to another rough section. A distance between two adjacent rough sections is at least 10 μm or more, and the rough section has an uneven structure with a height ranging from 20 nm to 200 nm on the surface.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Aono, Masashi
Kasai, Seiya
Ohkoda, Kaori
Fukuda, Shingo
Abstract
A solution-searching system encompasses an output adjustment unit having N signal adjustment circuits for converting provisional output-adjustment signals into final output-adjustment signals, 2N data generation units for generating binary data, 2N data conversion units which convert the binary data into information, a fluctuation setting unit for suppling bias probabilities to the signal adjustment circuits, fluctuation probabilities to the data generation units, and threshold values to the data conversion units, setting occurrence-frequencies of the binary data for making an occurrence-frequency of a specific variable, and a feedback control unit for determining whether an optimal solution has been found based on the information converted by the data conversion units and search-problem information preliminarily entered, by repeating transmission of the final output-adjustment signals to the output adjustment units, if the optimal solution has not been found.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Lei, Miaomei
Nakamura, Takahiro
Takemoto, Takashi
Mayama, Michinori
Abstract
An object of the invention is to improve reliability of an annotation. A collation apparatus includes: a grouping processing unit configured to group, based on each explanatory variable of a sample group, the sample group into a first group indicating a first classification and a second group indicating a second classification having a lower evaluation than the first classification; a collation unit configured to collate the classification of the first group and the second group that are obtained by the grouping processing unit with a classification identified by each objective variable of the sample group; and an output unit configured to output a collation result obtained by the collation unit.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Ito, Hajime
Kubota, Koji
Abstract
A method for producing an organometallic nucleophile includes reacting an organohalide and a metal or metal compound with each other by a mechanochemical process in the presence of an ether compound in an amount of 0.5 to 10.0 equivalents relative to 1 equivalent of the organohalide. By utilizing the method, a method for producing an organometallic nucleophile can be performed without using a large-scale apparatus, a reaction method for reactions between an organometallic nucleophile and various organic electrophiles can be performed by an efficient and simplified means, and a simplified method for producing an organometallic nucleophile can be performed with high reactivity.
National University Corporation Hokkaido University (Japan)
Inventor
Kono, Naoya
Fujiwara, Naoki
Saitoh, Kunimasa
Fujisawa, Takeshi
Sato, Takanori
Abstract
A semiconductor optical device includes a substrate formed of silicon and having a first optical waveguide and a semiconductor element formed of a III-V compound semiconductor and having a second optical waveguide, the semiconductor element being bonded to an upper surface of the substrate. The first optical waveguide and the second optical waveguide form a directional coupler.
H01S 5/10 - Construction or shape of the optical resonator
H01S 5/22 - Structure or shape of the semiconductor body to guide the optical wave having a ridge or a stripe structure
H01S 5/343 - Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser
42.
Information processing system and spectroscopic measuring instrument
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Takahashi, Yukihiro
Ono, Tatsuharu
Naruse, Nobuyasu
Ishida, Yurino
Abstract
An information processing system includes a storage, an interface device, and a computing circuit. The storage stores a database, in which spectrum data concerning light from a light source and a measurement condition data at a time of measurement of the light are associated with a plant status data concerning growth of a plant and/or a harvest data concerning a harvest of the plant. The interface device receives an input of a user measurement condition which is to be applied at a time of measurement of the plant by a user and which includes data concerning angles at the time of measurement and data concerning a plant status and/or a harvest to be predicted. The computing circuit determines at least two wavelengths contained in the light from the light source to be measured under the user measurement condition by referring to the database based on the user measurement condition.
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
ACQUISITION METHOD OF VALUE RELATING TO TRIGLYCERIDE METABOLIC CAPACITY, PRESENTATION METHOD OF DISEASE INFORMATION, PRESENTATION METHOD OF DISEASE DIFFERENTIATION INFORMATION, PRESENTATION METHOD OF THERAPY EFFICACY INFORMATION, PRESENTATION METHOD OF THERAPEUTIC EFFECT INFORMATION, TEST REAGENT AND TEST KIT
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Hirano, Ken-Ichi
Hara, Yasuhiro
Kashiwagi, Hirokazu
Suzuki, Akira
Jin, Takashi
Monde, Kenji
Murai, Yuta
Abstract
Provided are a method for acquiring a value relating to a triglyceride metabolic capacity of a subject within a shorter period of time compared to conventional nuclear medicine methods, and a test reagent and a test kit that are to be used in the acquisition method. This problem can be solved by an acquisition method of a value relating to the triglyceride metabolic capacity in leucocytes of a subject, said method comprising: a first step of mixing, in vitro, a fatty acid compound labeled with a fluorescent substance with leucocytes collected from the subject and thus bringing the fatty acid labeled with the fluorescent substance into contact with the leucocytes, wherein the fatty acid compound contains a fatty acid residue, the fatty acid residue has 8-26 carbon atoms, and a part of hydrogen atoms constituting the fatty acid residue, excluding a terminal methyl group of the fatty acid residue, may be substituted by an alkyl group having 1-3 carbon atoms; and a second step of acquiring, as the value relating to the triglyceride metabolic capacity, a measured fluorescence intensity that is derived from the fluorescent label in the leucocytes.
G01N 33/92 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol
G01N 33/533 - Production of labelled immunochemicals with fluorescent label
C07C 229/34 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Takahashi, Yukihiro
Moteki, Youhei
Naruse, Nobuyasu
Abstract
The spectroscopic measuring instrument includes: a spectrometer to make measurement of a reflection spectrum of an object relative to a light source and output measurement information representing a result of the measurement; a shadow projector including obstacle(s) to allow light from the light source to cast shadow(s) on an object surface; an imaging device to output image information representing an image of an imaging area including the object surface; a storage interface removably connectable to a computer readable medium; and a processing device. The processing device is connected to the spectrometer, the imaging device and the storage interface, and performs a measurement process of storing the measurement information from the spectrometer and the image information from the imaging device in the computer readable medium connected to the storage interface.
National University Corporation Hokkaido University (Japan)
Inventor
Sakai, Ryuichi
Nakano, Koji
Abstract
A polypeptide that comprises the amino acid sequence of SEQ ID NO: 1 and has a function of delivering a substance into cells, a polypeptide that comprises the amino acid sequence of SEQ ID NO: 2 and has a function of degrading a nucleic acid molecule, a polypeptide that comprises the amino acid sequence of SEQ ID NO: 3 and has a function of degrading a nucleic acid molecule and a function of intranuclearly migrating the same, polynucleotides encoding the respective polypeptides, and transformed cells containing the respective polynucleotides.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Johmen, Masayoshi
Obata, Kazuhito
Setoguchi, Shinichi
Kawaguchi, Toshikazu
Ito, Ryusei
Guizani, Mokhtar
Abstract
An electrochemical sensor is used in a state of being immersed in water to be inspected for water quality inspection. The electrochemical sensor includes a working electrode, a reference electrode, a first counter electrode, and a second counter electrode. The working electrode, the reference electrode, the first counter electrode, and the second counter electrode are electrically isolated from each other.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Furukawa, Jun-Ichi
Sakamoto, Naoya
Hanamatsu, Hisatoshi
Ogawa, Koji
Suda, Goki
Abstract
A method for evaluating the progression of hepatic fibrosis in non-alcoholic steatohepatitis, said method comprising measuring the amount of a sugar chain having a structure represented by formula (I) and/or a precursor sugar chain of the biosynthesis of a sugar chain having a structure represented by formula (I) in a sample.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Aoki, Yoshitaka
Abstract
An object of the present invention is to provide a hydrogen permeable material having excellent hydrogen permeability. Another object of the present invention is to provide a composite member and a fuel cell including the hydrogen permeable material. The hydrogen permeable material comprises a perovskite type compound represented by the following general formula (1a). In another embodiment, the hydrogen permeable material comprises a hydrogen-containing perovskite type compound, which is the perovskite type compound represented by the general formula (1a) with introduced hydride ion (H−). Wherein M is at least one alkaline earth metal selected from the group consisting of Ba, Sr and Ca, x is a numerical value of 0 or more and 0.3 or less, y is a numerical value of more than 0 and 0.75 or less, w is a value at which an average valence of In is +1.0 or more and +2.5 or less, and y≥w.
An object of the present invention is to provide a hydrogen permeable material having excellent hydrogen permeability. Another object of the present invention is to provide a composite member and a fuel cell including the hydrogen permeable material. The hydrogen permeable material comprises a perovskite type compound represented by the following general formula (1a). In another embodiment, the hydrogen permeable material comprises a hydrogen-containing perovskite type compound, which is the perovskite type compound represented by the general formula (1a) with introduced hydride ion (H−). Wherein M is at least one alkaline earth metal selected from the group consisting of Ba, Sr and Ca, x is a numerical value of 0 or more and 0.3 or less, y is a numerical value of more than 0 and 0.75 or less, w is a value at which an average valence of In is +1.0 or more and +2.5 or less, and y≥w.
M1-xZr1-yInyO3-x-0.5y-2 (1a)
H01M 8/1253 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides the electrolyte containing zirconium oxide
H01M 8/126 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides the electrolyte containing cerium oxide
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Ogawa, Mikako
Takakura, Hideo
Matsuhiro, Shino
Inanami, Osamu
Abstract
A method for decomposing a compound represented by Formula (1) includes irradiating the compound with X-rays in a presence of an electron donor:
A method for decomposing a compound represented by Formula (1) includes irradiating the compound with X-rays in a presence of an electron donor:
A method for decomposing a compound represented by Formula (1) includes irradiating the compound with X-rays in a presence of an electron donor:
wherein R111, R121, R131, and R141 each independently represent a monovalent organic group; p, q, r, and s each independently represent an integer of 0 or 1 to 4; in the case where two or more R111, R121, R131, and R141 are present, they may be identical to or different from one another or may be bonded to one another to form a ring; A101 represents a monovalent organic group; and A102 represents a hydrogen atom or a monovalent organic group). In the method, a photosensitive dye can be decomposed using an energy beam which can penetrate deeper into a living body than near-infrared light and activate the photosensitive dye.
National University Corporation Hokkaido University (Japan)
UACJ Corporation (Japan)
Inventor
Kikuchi, Tatsuya
Sato, Miu
Nunomura, Junji
Oya, Yoshiyuki
Abstract
An aluminum member (1) includes: a base material (2) composed of aluminum or an aluminum alloy; and an anodic oxide film (3) formed on a surface of the base material. The anodic oxide film includes: an amorphous layer (31), which is composed of an amorphous aluminum oxide and is formed on the base material (2); and a crystal layer (32), which is composed of a crystalline aluminum oxide and is formed on the amorphous layer (31). The aluminum member (1) can be obtained by forming the anodic oxide film (3) on the base material (2) by performing an anodization process on the base material (2) in an electrolytic solution, which contains boron atoms and has a pH of 7.0-12.0.
National University Corporation Hokkaido University (Japan)
Inventor
Imai, Yasuyuki
Hirahashi, Tomohiro
Kasahara, Masanori
Miyazaki, Aya
Seya, Tsukasa
Matsumoto, Misako
Tomaru, Utano
Abstract
A composition for activating cytotoxic T lymphocytes (CTLs) containing a spirulina extract is provided. A composition for CTL activation for proliferation of cytotoxic T lymphocytes (CTLs) containing a spirulina extract is provided. Moreover, a pharmaceutical composition for CTL activation or a food or a drink for CTL activation containing the composition for CTL activation is provided.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Tachibana, Yuki
Uehara, Shota
Unoh, Yuto
Nakahara, Kenji
Taoda, Yoshiyuki
Yamatsu, Yukiko
Ando, Shigeru
Sasaki, Michihito
Abstract
The present invention provides a compound exhibiting coronavirus 3 CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same.
A compound represented by Formula:
or a pharmaceutically acceptable salt thereof.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
53.
CATALYST STRUCTURE FOR SYNTHESIS GAS PRODUCTION, SYNTHESIS GAS PRODUCTION APPARATUS, AND METHOD FOR PRODUCING CATALYST STRUCTURE FOR SYNTHESIS GAS PRODUCTION
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Banba, Yuichiro
Fukushima, Masayuki
Ueno, Takahiro
Mori, Tomohiko
Nishii, Mai
Masuda, Takao
Nakasaka, Yuta
Yoshikawa, Takuya
Abstract
A catalyst structure for synthesis gas production of a synthesis gas that contains carbon monoxide and hydrogen, the catalyst structure being provided with a carrier that has a porous structure, while being configured from a zeolite type compound; first catalyst particles that contain one or more iron group elements which are selected from the group consisting of nickel (Ni), iron (Fe) and cobalt (Co); and second catalyst particles that contain one or more platinum group elements which are selected from the group consisting of platinum (Pt), palladium (Pd), rhodium (Rh) and ruthenium (Ru). The catalyst structure for synthesis gas production has passages in communication with each other within the carrier. The first catalyst particles are present at least in the passages of the carrier; and the second catalyst particles are present at least either inside the carrier or on the outer surface of the carrier.
B01J 29/035 - Crystalline silica polymorphs, e.g. silicalites
B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
B01J 35/10 - Solids characterised by their surface properties or porosity
B01J 37/02 - Impregnation, coating or precipitation
C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
54.
Functional structural body and method for making functional structural body
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
FURUKAWA ELECTRIC CO., LTD. (Japan)
Inventor
Masuda, Takao
Nakasaka, Yuta
Yoshikawa, Takuya
Kato, Sadahiro
Fukushima, Masayuki
Inamori, Kojiro
Takahashi, Hiroko
Banba, Yuichiro
Sekine, Kaori
Abstract
To provide a functional structural body that can realize a long life time by suppressing the decline in function of the functional substance and that can attempt to save resources without requiring a complicated replacement operation, and to provide a method for making the functional structural body. The functional structural body (1) includes a skeletal body (10) of a porous structure composed of a zeolite-type compound, and at least one functional substance (20) present in the skeletal body (10), the skeletal body (10) has channels (11) connecting with each other, and the functional substance is present at least in the channels (11) of the skeletal body (10).
B01J 29/08 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the faujasite type, e.g. type X or Y
B01J 29/10 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the faujasite type, e.g. type X or Y containing iron group metals, noble metals or copper
B01J 29/16 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the faujasite type, e.g. type X or Y containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
B01J 29/18 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the mordenite type
B01J 29/20 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the mordenite type containing iron group metals, noble metals or copper
B01J 29/26 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the mordenite type containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
B01J 29/40 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11
B01J 29/42 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11 containing iron group metals, noble metals or copper
B01J 29/64 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the type L containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
B01J 29/65 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the ferrierite type, e.g. types ZSM-21, ZSM-35 or ZSM-38
B01J 29/66 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the ferrierite type, e.g. types ZSM-21, ZSM-35 or ZSM-38 containing iron group metals, noble metals or copper
B01J 29/69 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the ferrierite type, e.g. types ZSM-21, ZSM-35 or ZSM-38 containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
B01J 29/70 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of types characterised by their specific structure not provided for in groups
B01J 29/72 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of types characterised by their specific structure not provided for in groups containing iron group metals, noble metals or copper
B01J 29/78 - Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of types characterised by their specific structure not provided for in groups containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Oyamada, Takayoshi
Shimada, Toshio
Kakita, Kosuke
Iwata, Hiroaki
Abstract
It is an object of the present invention to provide a Japanese encephalitis preventive agent and a Japanese encephalitis vaccine agent, which are capable of imparting sufficient immunity to humans, even if these agents are used at a lower dose than the dose of a Japanese encephalitis vaccine for subcutaneous injection, or at a smaller number of administrations than the number of administrations of a Japanese encephalitis vaccine for subcutaneous injection. According to the present invention, provided is a Japanese encephalitis preventive agent, comprising a microneedle array having a sheet portion and a plurality of needle portions present on the upper surface of the sheet portion, wherein the aforementioned needle portions contain or carry an inactivated Japanese encephalitis virus.
National University Corporation Hokkaido University (Japan)
Robert Reid, Inc. (Japan)
Inventor
Sudo, Hideki
Kanai, Satoshi
Kokabu, Terufumi
Abe, Yuichiro
Segawa, Tsuyoshi
Abstract
A rod group includes a plurality of first rods that has an arcuate first curve, the first rods having mutually different lengths; and a plurality of second rods that has an S-shaped second curve, the second rods having mutually different lengths. The first rods and the second rods have shapes for treatment of scoliosis by (i) guiding the postoperative apex of the thoracic kyphosis to be located at the thoracic vertebrae T6 to T8, and (ii) guiding a postoperative apex of the thoracic kyphosis to be located at a position different from a preoperative apex of the thoracic kyphosis and the second rod each have a shape extending along an anatomically normal spinal column arrangement.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
MORINAGA MILK INDUSTRY CO., LTD. (Japan)
Hitachi, Ltd. (Japan)
Inventor
Suzuki, Daisuke
Lei, Miaomei
Tamakoshi, Akiko
Yokota, Takashi
Nakamura, Kiminori
Takeda, Yasuhiro
Ehara, Tatsuya
Abstract
A parent-and-child health study assistance system includes a data management section managing health study data used for a health study of at least one of a parent and a child in a family including a user as a family member, a level calculation section calculating a contribution level for the health study of the user based on input of the health study data, an incentive provision section providing the user with an incentive used as a profit corresponding to the contribution level, in conjunction with input of the health study data, an access control section managing an access authority to access the health study data, and an analysis result provision section providing an analysis result of analysis processing using the health study data.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G06Q 30/0208 - Trade or exchange of goods or services in exchange for incentives or rewards
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules
National University Corporation Hokkaido University (Japan)
Inventor
Sugaya, Tsutomu
Yamada, Keita
Ban, Shingo
Dokai, Kei
Ueda, Tomoaki
Yamaguchi, Shunsuke
Matoba, Kazunari
Abstract
A treatment device that shortens the time period until healing is determined even when a bone defect or a root apex lesion is generated in an apical area. The treatment device includes a file holder, a high-frequency signal generating circuit, and a control circuit. The file holder holds a file to be located in the site to be treated. The high-frequency signal generating circuit passes a high frequency current through the file. The control circuit controls a frequency of the high frequency current to be passed through the file from the high-frequency signal generating circuit. The control circuit controls the frequency of the high frequency current to be passed through the file within a range of 1.001 MHz to 11.700 MHz.
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
A61C 5/40 - Implements for surgical treatment of the roots or nerves of the teeth; Nerve needles; Methods or instruments for medication of the roots
59.
OXIDE-CONTAINING COPPER FINE PARTICLES, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING SINTERED COMPACT USING OXIDE-CONTAINING COPPER FINE PARTICLES
National University Corporation Hokkaido University (Japan)
Inventor
Yonezawa, Tetsu
Abstract
Disclosed is oxide-containing copper fine particles including Cu64O and optionally Cu2O and coated with a carboxylic acid, wherein a mass ratio of Cu64O to a total mass of Cu, Cu64O and Cu2O is 0.5 to 2.0% by mass.
B22F 1/102 - Metallic powder coated with organic material
B22F 9/04 - Making metallic powder or suspensions thereof; Apparatus or devices specially adapted therefor using physical processes starting from solid material, e.g. by crushing, grinding or milling
B22F 7/04 - Manufacture of composite layers, workpieces, or articles, comprising metallic powder, by sintering the powder, with or without compacting of composite layers with one or more layers not made from powder, e.g. made from solid metal
60.
Method for Producing Mono-Cross-Coupled Aromatic Compound Having Leaving Group
National University Corporation Hokkaido University (Japan)
Inventor
Ito, Hajime
Kubota, Koji
Abstract
Disclosed is a method for producing a mono-cross-coupled aromatic compound (3-1) having one less leaving group than an aromatic compound (1) having at least two leaving groups, the method comprising: preparing the aromatic compound (1) having at least two leaving groups; preparing a compound (2) capable of undergoing a cross-coupling reaction selected from an aromatic boronic acid (2-1), an aromatic amino compound (2-2), a diboronic acid ester (2-3), an aromatic compound (2-4) having a hydroxyl group and an aromatic compound (2-5) having a thiol group; and performing a cross-coupling reaction of the aromatic compound (1) having at least two leaving groups with the compound (2) in the presence of a palladium catalyst and a base, in the absence of a solvent.
C07C 209/68 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
C07C 41/30 - Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
C07C 17/263 - Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
C07C 1/30 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from organic compounds containing only halogen atoms as hetero atoms by splitting-off the elements of hydrogen halide from a single molecule
C07C 17/269 - Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of only halogenated hydrocarbons
C07D 333/16 - Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
C07D 333/22 - Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
C07D 333/56 - Radicals substituted by oxygen atoms
C07C 1/32 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from compounds containing hetero atoms other than, or in addition to, oxygen or halogen
61.
PARENT-CHILD HEALTH MANAGEMENT SYSTEM, PARENT-CHILD HEALTH ANALYSIS DEVICE, AND PARENT-CHILD HEALTH MANAGEMENT METHOD
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
MORINAGA MILK INDUSTRY CO., LTD. (Japan)
Hitachi, Ltd. (Japan)
Inventor
Nakamura, Takahiro
Takemoto, Takashi
Yoshino, Masanori
Ayabe, Tokiyoshi
Kimura, Takashi
Izumi, Hirohisa
Tabata, Fuka
Abstract
An analysis device in a parent-child health management system receives a sensor output from a sensor terminal and an answer to a questionnaire from a user terminal. At least one of parent's life information and child's life information is analyzed based on the answer to the questionnaire to generate a life information analysis result. A sensor output analysis unit generates, based on the sensor output, a sensing result including at least one of a parent-child relationship, a parent's health condition, and a child's health condition. A health estimation unit is configured to compare the life information analysis result and the sensing result with a predetermined criterion to estimate at least one of a parent-child state, a parent's state, and a child's state. An output unit is configured to select a questionnaire and advice corresponding to the estimated state and output the selected questionnaire and advice to the user terminal.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
62.
LIPID MEMBRANE STRUCTURE FOR DELIVERY INTO SIRNA CELL
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Harashima, Hideyoshi
Sato, Yusuke
Abstract
A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I):
A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I):
A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I):
[in the formula, a represents an integer of 3 to 5; b represents an integer of 0 or 1; R1 and R2 each independently represents a linear hydrocarbon group that may have —CO—O—; and X represents a 5- to 7-membered non-aromatic heterocyclic group or a group represented by Formula (B) (in the formula, d represents an integer of 0 to 3, and R3 and R4 each independently represents a C1-4 alkyl group or a C2-4 alkenyl group, where, R3 and R4 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (where, one or two C1-4 alkyl groups or C2-4 alkenyl groups may be substituted on the ring)].
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07D 211/32 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
C07D 295/03 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
63.
FOOD ANIMAL FRESHNESS/DEGREE OF MATURATION EVALUATING DEVICE, AND FRESHNESS/DEGREE OF MATURATION EVALUATING METHOD
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Inada, Takaaki
Nagaishi, Hiroshi
Tsubouchi, Naoto
Shinohara, Yuji
Abstract
A freshness/degree of maturation evaluating device for evaluating freshness and/or degree of maturation of food animal, freshness/degree of maturation evaluating device provided with: temperature parameter calculation unit that calculates temperature parameter regarding storage time and temperature in arbitrary area inside food animal, parameter based on temperature in arbitrary area inside food animal, determined by storage time and unsteady heat conduction equation; rate constant parameter calculation unit that calculates rate constant parameter regarding sequential decomposition reactions of various ATP-associated compounds contained infood animal, parameter being set based on rate constants in food animal determined by using relation based on storage time of food animal and measured values of ATP-associated compound concentrations; ATP-associated compound concentration calculation unit that calculates ATP-associated compound concentrations by sequential decomposition reaction calculation model using temperature parameter and rate constant parameter; and freshness/degree of maturation evaluation unit that computes K value and/or FI value from ATP-associated compound concentrations.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Tachibana, Yuki
Uehara, Shota
Unoh, Yuto
Nakahara, Kenji
Taoda, Yoshiyuki
Kasamatsu, Koji
Yamatsu, Yukiko
Ando, Shigeru
Iimuro, Atsuhiro
Suto, Takahiro
Sasaki, Michihito
Abstract
The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same.
The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same.
A compound represented by Formula (I):
The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same.
A compound represented by Formula (I):
wherein Y is N or the like; R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is substituted or unsubstituted aromatic carbocyclyl or the like; R3 is substituted or unsubstituted aromatic heterocyclyl or the like; —X— is —NH— or the like; m is 1 or the like; R5a is each independently a hydrogen atom or the like; R5b is each independently a hydrogen atom or the like; n is 1 or the like; R4a is each independently a hydrogen atom or the like; and R4b is each independently a hydrogen atom or the like,
or a pharmaceutically acceptable salt thereof.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
MORINAGA MILK INDUSTRY CO., LTD. (Japan)
Hitachi, Ltd. (Japan)
Inventor
Nakamura, Takahiro
Takemoto, Takashi
Yoshino, Masanori
Ayabe, Tokiyoshi
Kimura, Takashi
Izumi, Hirohisa
Tabata, Fuka
Abstract
A mother and child health management system is connected to a plurality of terminals and includes: a reception unit configured to receive, as analysis information, information from each of the plurality of terminals and biological information from a medical care institution; a classification unit configured to identify, based on an analysis result of the analysis information, state values indicating a state of a mother, a state of a child, and a state between the mother and the child; an access authority management section configured to identify, based on each of the state values, a community to which a family including a user of the each of the plurality of terminals belongs, and configured to provide the terminal with an access authority to receive a display of a solution related to the community; and a display unit configured to display the solution related to the community on the terminal.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
NATIONAL UNIVERSITY COPORATION HOKKAIDO UNIVERSITY (Japan)
SHIONOGI & CO., LTD. (Japan)
Inventor
Ishii, Akihiro
Sato, Akihiko
Kawai, Makoto
Taoda, Yoshiyuki
Abstract
The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound.
An arenavirus proliferation inhibitor comprising a compound represented by Formula (I) or a prodrug thereof or a pharmaceutically acceptable salt thereof:
11 are each independently a hydrogen atom, carboxy, cyano, alkyl optionally substituted with Substituent group F, or the like).
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
National University Corporation Hokkaido University (Japan)
Inventor
Kadoya, Ken
Suzuki, Yuki
Sotome, Akihito
Maenaka, Katsumi
Otsuguro, Satoko
Abstract
The present invention relates to an agent for protection of vascular endothelial cells, an agent for protection of blood brain spinal cord barrier, and an agent for protection of central nervous system, containing at least one compound selected from the group consisting of muvritinib, brexpiprazole, papaverine, bismuth-containing compounds, and pharmaceutically acceptable salts thereof. The invention also relates to a pharmaceutical composition for the treatment of diseases associated with blood brain spinal cord barrier disruption, containing at least one compound selected from the group consisting of muvritinib, brexpiprazole, papaverine, bismuth-containing compounds, and pharmaceutically acceptable salts thereof.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (Japan)
Inventor
Harashima, Hideyoshi
Sato, Yusuke
Abbasi, Saed Amjad Yousef
Yamashita, Shinji
Higashino, Haruki
Abstract
The present invention addresses the problem of providing a dissolving agent which improves the solubility of a compound such as curcumin that contains an aromatic ring without changing the structure of this compound. The present invention is a compound which is represented by general formula (1). (In the formula, R1 is an alkyl group having 7 to 24 carbon atoms or an alkenyl group; A1 represents an optionally substituted aryl group; Z1 represents a single bond, an alkylene group having from 1 to 6 carbon atoms, or an alkenylene group having from 2 to 5 carbon atoms; and Z2 represents a divalent linking group.)
The present invention addresses the problem of providing a dissolving agent which improves the solubility of a compound such as curcumin that contains an aromatic ring without changing the structure of this compound. The present invention is a compound which is represented by general formula (1). (In the formula, R1 is an alkyl group having 7 to 24 carbon atoms or an alkenyl group; A1 represents an optionally substituted aryl group; Z1 represents a single bond, an alkylene group having from 1 to 6 carbon atoms, or an alkenylene group having from 2 to 5 carbon atoms; and Z2 represents a divalent linking group.)
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Shuto, Satoshi
Matsuda, Tadashi
Muromoto, Ryuta
Fukuda, Hayato
Abstract
The present invention provides a compound represented by General Formula (1) or (1′) [in the formula, R1 and R2 each independently represents a hydrogen atom or a hydroxy group; R3 represents an alkyl group having 1 to 6 carbon atoms; R4 represents a halogen atom or an alkyl group; m indicates the number of R4 and represents an integer of 0 to 4; in a case where m is 2 or more, a plurality of R4's may be the same or different from each other; n represents an integer of 1 to 6; and n′ represents an integer of 1 to 4] and a neutrophil infiltration suppressor containing the compound as an active ingredient.
The present invention provides a compound represented by General Formula (1) or (1′) [in the formula, R1 and R2 each independently represents a hydrogen atom or a hydroxy group; R3 represents an alkyl group having 1 to 6 carbon atoms; R4 represents a halogen atom or an alkyl group; m indicates the number of R4 and represents an integer of 0 to 4; in a case where m is 2 or more, a plurality of R4's may be the same or different from each other; n represents an integer of 1 to 6; and n′ represents an integer of 1 to 4] and a neutrophil infiltration suppressor containing the compound as an active ingredient.
National University Corporation Hokkaido University (Japan)
Inventor
Hiratani, Takuo
Fujiwara, Naoki
Saitoh, Kunimasa
Fujisawa, Takeshi
Sato, Takanori
Abstract
An optical filter includes a first loop mirror, a second loop mirror, a first waveguide optically coupled to the first loop mirror and the second loop mirror, a second waveguide optically coupled to the first loop mirror and the second loop mirror, a first access waveguide optically coupled to the first waveguide, a second access waveguide optically coupled to the second waveguide, and an output section, wherein the first loop mirror includes a first loop waveguide and a first multiplexer/demultiplexer, the second loop mirror includes a second loop waveguide and a second multiplexer/demultiplexer, the output section includes a third loop waveguide, a third multiplexer/demultiplexer, a third waveguide, and a fourth waveguide, the third loop waveguide optically coupled to the second loop waveguide and the third multiplexer/demultiplexer, the third waveguide and the fourth waveguide optically coupled to the third multiplexer/demultiplexer, and the output section.
G02B 6/12 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Kitagawa, Yuichi
Naito, Ayu
Hasegawa, Yasuchika
Fushimi, Koji
Abstract
Disclosed is a rare earth complex including: one or a plurality of rare earth ions; and a ligand forming a coordinate bond with the rare earth ions. At least a part of the rare earth ions are at least one kind selected from the group consisting of lutetium(III) ions, yttrium(III) ions, and gadolinium(III) ions. The ligand includes a residue obtained by removing one or more hydrogen atoms from a fluorescent condensed polycyclic aromatic compound.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Matsumoto, Kenichiro
Fukui, Toshiaki
Ishihara, Shizuru
Abstract
A copolymer comprising: a hydroxycarboxylic acid (A) having a hydroxy group only at a 2-position; and a hydroxycarboxylic acid (B) having a hydroxy group at a position other than a 2-position, and having a homopolymer segment composed of one hydroxycarboxylic acid selected from the group consisting of the hydroxycarboxylic acid (A) and the hydroxycarboxylic acid (B), and a copolymer segment containing at least two hydroxycarboxylic acids selected from the group consisting of the hydroxycarboxylic acid (A) and the hydroxycarboxylic acid (B).
C08G 63/06 - Polyesters derived from hydroxy carboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxy carboxylic acids
73.
CARTILAGE DAMAGE TREATMENT MATERIAL UTILIZING BONE MARROW FLUID
National University Corporation Hokkaido University (Japan)
Mochida Pharmaceutical Co., Ltd. (Japan)
Inventor
Iwasaki, Norimasa
Onodera, Tomohiro
Urita, Atsushi
Jo, Ryo
Abstract
Provided is a composition for treating cartilage injury lesion that is combined with a concentrated bone marrow aspirate and applied to a cartilage injury lesion, that has flowability when applied to the cartilage injury lesion, and that contains a monovalent metal salt of alginic acid. Thereby, a novel composition for treating cartilage injury lesion that can be used to restore and/or regenerate cartilage tissue is provided.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (Japan)
Inventor
Satoh, Noriyuki
Ito, Yasuki
Sakurai, Toshihiro
Mizuta, Masahiro
Hui, Shu-Ping
Nouso, Kazuhiro
Okada, Hiroyuki
Abstract
Provided is a method of assisting the detection of nonalcoholic steatohepatitis (NASH), which is far less invasive than liver biopsy and is based on simple operations that do not require skilled technical personnel.
Provided is a method of assisting the detection of nonalcoholic steatohepatitis (NASH), which is far less invasive than liver biopsy and is based on simple operations that do not require skilled technical personnel.
The present invention is a method of assisting the detection of NASH, which includes:
a) measuring the amount of LDL-TG contained in a test blood sample isolated from a living body;
b) measuring the amount of at least one component selected from the group consisting of LDL-C, LDL subfraction-C, IIDL-C, HDL subfraction-C, ApoB, ApoE, total cholesterol, ALT, and AST contained in the test blood sample; and
c) determining the possibility of developing and/or having NASH by using the amount of LDL-TG in combination with the amount of the at least one component.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Nakamura, Naoki
Nakano, Tamaki
Abstract
To provide a proton conductive material which has high proton conductivity even under no humidification and does not elute into water. A proton conductive material comprising a proton-source-polymer and a proton-channel-polymer, wherein at least one selected from the group consisting of the proton-source-polymer and the proton-channel-polymer is a polymer containing an aromatic ring, and wherein at least a part of the polymer containing the aromatic ring has a stacked structure formed by n-n interactions, and a proton conductive material comprising a proton-source-crosslinked-polymer, wherein the proton-source-crosslinked-polymer is a polymer having a main skeleton which contains a proton source group and an aromatic ring, and a crosslinked structure which contains a proton channel, and wherein at least a part of the proton-source-crosslinked-polymer has a stacked structure formed by n-n interactions.
H01M 8/1032 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having sulfur, e.g. sulfonated-polyethersulfones [S-PES]
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Takai, Tomokazu
Mizuno, Hitoshi
Takahashi, Akira
Endo, Toshiya
Sakaue, Shinichi
Iwasaki, Norimasa
Onodera, Tomohiro
Iwasaki, Koji
Abstract
Realized is reliable fixation of a material in a fluid state containing a monovalent metal salt of alginic acid when the material is applied to a subject. A combination of compositions comprising a first material composition containing a monovalent metal salt of alginic acid and a second material composition containing a cross-linking agent having an action of cross-linking the monovalent metal salt of alginic acid, wherein the combination is to be used in such a way as to apply the first material composition to a subject in a fluid state and contact the second material composition with the first material composition applied to the subject to gel at least a part of the first material composition, wherein the first material composition further contains a coloring component so that a formation state of a gel coat on a surface of the first material composition applied to the subject can be evaluated.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Kono, Naoya
Fujiwara, Naoki
Saitoh, Kunimasa
Fujisawa, Takeshi
Sato, Takanori
Abstract
An optical filter includes a first loop mirror, a second loop mirror, a first waveguide optically coupled to the first loop mirror and the second loop mirror, and a first access waveguide. The first loop mirror includes a first loop waveguide and a first multiplexer/demultiplexer. The second loop mirror includes a second loop waveguide and a second multiplexer/demultiplexer. The first loop waveguide is optically coupled to the first multiplexer/demultiplexer. The second loop waveguide is optically coupled to the second multiplexer/demultiplexer. The first waveguide is optically coupled to the first multiplexer/demultiplexer and the second multiplexer/demultiplexer. The first access waveguide is optically coupled to the first waveguide.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Mizuno, Hitoshi
Masuda, Kuniyoshi
Katayama, Masahiko
Takai, Tomokazu
Endo, Toshiya
Iwasaki, Norimasa
Onodera, Tomohiro
Iwasaki, Koji
Abstract
A retractor is provided that can form a joint cavity internal space for a field of view for an endoscope and practice of a treatment in a state where a wound area is spread. A retractor includes first arm portions 2 and 3 and a second arm portion 4 positioned between the first arm portions 2 and 3. The first arm portions 2 and 3 include first claw portions 12 and 13 to be hung on a wound area entrance edge. The second arm portion 4 includes a second claw portion 14 to be hung on the wound area entrance edge. When the first arm portions 2 and 3 and the second arm portion 4 are in a closed state, the first claw portions 12 and 13 and the second claw portion 14 overlap with each other.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Atarashi, Hiroki
Nakahara, Kenji
Abstract
The present invention addresses the problem of providing: a solanaceous plant and a solanaceous plant cell that have resistance to tomato spotted wilt virus (TSWV) and that have the property of inhibiting TSWV infection, the property of suppressing the propagation proliferation of TSWV after infection, and/or the property of suppressing the onset of the symptoms of TSWV infection; and a method for producing the solanaceous plant. The present invention provides a solanaceous plant that has resistance to TSWV, in which at least one gene selected from the group consisting of receptor-like kinase RLK genes and homologous genes thereof has a mutation, and in which as a result of the mutation, either the expression of the gene having the mutation is suppressed or a protein encoded by the gene having the mutation is non-functional with respect to TSWV.
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
80.
CATALYST, METHOD FOR PRODUCING ISOBUTYL ALDEHYDE AND METHACROLEIN, METHOD FOR PRODUCING METHACRYLIC ACID, AND METHOD FOR PRODUCING METHACRYLIC ACID ESTER
C07C 29/153 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of oxides of carbon exclusively with hydrogen or hydrogen-containing gases characterised by the catalyst used
81.
METHOD FOR ASSESSING POSSIBILITY OF ONSET OR PROGRESSION OF CHRONIC KIDNEY ALLOGRAFT REJECTION AND CHRONIC KIDNEY DISEASE, TEST KIT, AND PHARMACEUTICAL COMPOSITION
National University Corporation Hokkaido University (Japan)
Inventor
Murakami, Masaaki
Kamimura, Daisuke
Takada, Yusuke
Abstract
The present invention provides a method for assessing the possibility of onset or progression of chronic kidney allograft rejection or chronic kidney disease in a test subject, by using, as an indicator, the level of SYT17 protein in a urine-derived specimen collected from the test subject. The present invention also provides: a pharmaceutical composition for preventing and/or treating chronic kidney allograft rejection or chronic kidney disease, the pharmaceutical composition including at least one substance selected from the group consisting of a specific antibody to SYT17, a derivative of the specific antibody, and an inhibitory nucleic acid against SYT17; and a test kit for use in assessing the possibility of onset or progression of chronic kidney allograft rejection or chronic kidney disease, the test kit including a specific antibody to SYT17 or a derivative of the specific antibody.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
82.
METHOD FOR SCREENING ANTICANCER AGENT AND COMBINATION DRUG OF KINASE INHIBITORS FOR TREATMENT OF PANCREATIC CANCER
National University Corporation Hokkaido University (Japan)
Inventor
Sonoshita, Masahiro
Sekiya, Sho
Hirano, Satoshi
Abstract
The present invention relates to a method for screening an anticancer agent by causing drosophila having the characteristics of a) expression of mutant Ras85D, b) deletion or suppressed expression of a p53 gene, c) overexpression of a cyclin E gene, and d) deletion or suppressed expression of a Med gene to ingest a test substance and comparing the survival rate thereof with the survival rate of drosophila that did not ingest the test substance. The present invention also relates to a combination drug of at least two kinase inhibitors for treatment of pancreatic cancer and to kinase inhibitors for use in said combination drug.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
83.
LATENT HEAT STORAGE BODY MICROCAPSULE AND METHOD FOR PRODUCING SAME
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Nomura, Takahiro
Kashiyama, Kohei
Sakai, Hiroki
Haga, Miki
Cho, Shunsuke
Sheng, Nan
Kawaguchi, Takahiro
Abstract
A latent heat storage body microcapsule includes a core including gallium or gallium alloy; and a shell covering the core and including gallium oxide. A method for producing the same includes a particle-forming step of forming gallium or an alloy of gallium in a liquid state into particles; a water treatment step of heating the particles in distilled water to form a gallium hydrate on a surface of each of the particles; and an oxidation treatment step of oxidizing the gallium hydrate to form a shell including gallium oxide. The method includes a particle-forming step of forming gallium or an alloy of gallium in a liquid state into particles; a cooling step of cooling the particles to a solid state; and a pH treatment step of immersing the particles in an aqueous solution having a predetermined pH to form a shell including gallium hydrate.
National University Corporation Hokkaido University (Japan)
Inventor
Maeki, Masatoshi
Tokeshi, Manabu
Harashima, Hideyoshi
Sato, Yusuke
Kimura, Niko
Abstract
The present invention pertains to a flow path structure body for forming self-assembling molecular particles. The flow path structure body has a base body and a flow path structure provided to the interior thereof, the flow path structure having a first introduction channel 10 and a second introduction channel 20 that are independent of one another on the upstream side of the flow path structure, and the introduction channels merging at a merging site. The flow path structure has a dilution flow path 40 that is bent three-dimensionally toward the downstream side of the merging site. The dilution flow path 40 has two or more Y structural elements 50 that protrude out in the Y direction and one or more Z structural elements 60 that protrude out in the Z direction within the dilution flow path, and at least two adjacent Y structural elements protrude out alternately in the Y direction. The present invention pertains to a method of producing self-assembling molecular particles, whereby a self-assembling molecule-containing solution and a dilution medium are supplied to the flow path structure body to form self-assembling molecular particles that have encapsulated a substance to be encapsulated. The present invention provides: a method of producing self-assembling molecular nanoparticles that enables precise control of the particle size of self-assembling molecular nanoparticles that have encapsulated an anionic molecule or the like at a high encapsulation rate; and a flow path structure body used for production.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Kondo, Toru
Abstract
An object is to provide a composition and a method for eliminating undifferentiated pluripotent stem cells remaining in a cell group induced to differentiate from pluripotent stem cells. It has been found that while dihydroorotate dehydrogenase inhibitors exhibit cytotoxic activity against pluripotent stem cells, they do not exhibit significant cytotoxic activity against differentiated cells such as somatic stem cells.
National University Comoration Hokkaido University (Japan)
Inventor
Ayabe, Tokiyoshi
Nakamura, Kiminori
Abstract
The purpose of the present invention is to provide a method for detecting, in a selective and simple manner, an oxidized form of HD5 which is human α-defensin, that is, HD5 having intramolecular disulfide bonds that function beneficially in the human body.
The purpose of the present invention is to provide a method for detecting, in a selective and simple manner, an oxidized form of HD5 which is human α-defensin, that is, HD5 having intramolecular disulfide bonds that function beneficially in the human body.
[Solution] The present invention relates to: two kinds of novel monoclonal antibodies that contain amino acid sequences of SEQ ID NO: 1-6 or 7-12 as a CDR and that specifically bind to human α-defensin HD5 having intramolecular disulfide bonds; an immunological detection method using the antibodies; and a kit containing the antibodies.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Matsunaga, Shigeki
Yoshino, Tatsuhiko
Matsuoka, Keitaro
Ogawa, Mikako
Abstract
This method for producing an aromatic astatine compound comprises reacting an aromatic iodonium ylide with astatine to produce an aromatic astatine compound.
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
C07D 209/48 - Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
C07C 69/712 - Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07D 215/16 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 333/62 - Benzo [b] thiophenes; Hydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
88.
Laminate, organic thin film solar cell, method for manufacturing laminate, and method for manufacturing organic thin film solar cell
National University Corporation Hokkaido University (Japan)
Inventor
Suto, Mikito
Masuoka, Hiroyuki
Matsuzaki, Akira
Habazaki, Hiroki
Kobayashi, Hikaru
Abstract
A laminate which allows to obtain an organic thin-film solar cell having excellent output characteristics and transparency is provided. The laminate as above has a titanium oxide layer that is disposed on the member serving as a light-transmissive electrode layer and serves as an electron transport layer. The titanium oxide layer has a thickness of not less than 1.0 nm and not more than 200.0 nm. The titanium oxide layer contains indium oxide and metallic indium, InOx/Ti is not less than 0.50 and not more than 20.00 in atomic ratio, and InM/Ti is less than 0.100 in atomic ratio, where an elemental titanium content is represented by Ti, an indium oxide content is represented by InOx, and a metallic indium content is represented by InM.
H01L 31/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
H10K 30/82 - Transparent electrodes, e.g. indium tin oxide [ITO] electrodes
H10K 30/30 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising bulk heterojunctions, e.g. interpenetrating networks of donor and acceptor material domains
H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
H10K 71/60 - Forming conductive regions or layers, e.g. electrodes
H10K 102/10 - Transparent electrodes, e.g. using graphene
89.
Heat-resistant alloy, heat-resistant alloy powder, heat-resistant alloy structural component, and manufacturing method of the same
TOKYO METROPOLITAN PUBLIC UNIVERSITY CORPORATION (Japan)
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Kakehi, Koji
Hayashi, Shigenari
Kuo, Yen-Ling
Abstract
A heat-resistant alloy contains at least one element selected from a group consisting of Al, Ti, Ni, Cr, and Mo, O, and Y, and a ratio of a content of Y in terms of mass to a content of O in terms of mass is 0.5 or greater and 100 or less.
C22C 19/05 - Alloys based on nickel or cobalt based on nickel with chromium
C22F 1/10 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of nickel or cobalt or alloys based thereon
C22C 1/04 - Making non-ferrous alloys by powder metallurgy
B33Y 70/00 - Materials specially adapted for additive manufacturing
B22F 1/00 - Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
90.
RARE EARTH COMPLEX, RARE EARTH COMPLEX SOLUTION, LUMINESCENT MOLDED ARTICLE, METHOD FOR PRODUCING LUMINESCENT PRODUCT, LUMINESCENT SHEET, AND VINYL GREENHOUSE FOR AGRICULTURE
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Kitagawa, Yuichi
Shima, Kaori
Wada, Satoshi
Hasegawa, Yasuchika
Fushimi, Koji
Abstract
Disclosed is a rare earth complex having a rare earth ion and a phosphine oxide ligand that is coordinated with the rare earth ion and is represented by the following formula (I):
Disclosed is a rare earth complex having a rare earth ion and a phosphine oxide ligand that is coordinated with the rare earth ion and is represented by the following formula (I):
wherein R1, R2, R3, R4, R5, and R6 each independently represent an alkyl group which may have a substituent.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Ito, Hajime
Kubota, Koji
Abstract
Disclosed are a method for producing a highly reactive intermediate, which comprises: preparing an electron-accepting active compound (1), preparing a piezoelectric material (3), and applying mechanical strain to the piezoelectric material (3) in the presence of the electron-accepting active compound (1) and the piezoelectric material (3), and subjecting the compound (1) to one-electron reduction to generate a corresponding highly reactive intermediate; a redox reaction method using the method for producing the same; and a method for producing a redox reaction product.
C07D 307/06 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
C07D 333/38 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
MICROCAPSULE FOR LATENT HEAT STORAGE MATERIALS, METHOD FOR PRODUCING SAME, POWDER CONTAINING MICROCAPSULES FOR LATENT HEAT STORAGE MATERIALS, AND HEAT STORAGE DEVICE COMPRISING SAID POWDER
National University Corporation Hokkaido University (Japan)
Inventor
Nomura, Takahiro
Kawaguchi, Takahiro
Sakai, Hiroki
Cho, Shunsuke
Kashiyama, Kohei
Sato, Kenji
Miya, Kazuyuki
Shibuya, Yoshitaka
Abstract
An object of the present invention is to provide a latent heat storage body which has a melting point of about 300 to 550° C. and is difficult to cause leakage of a phase changing material, and a product obtained by applying the body.
An object of the present invention is to provide a latent heat storage body which has a melting point of about 300 to 550° C. and is difficult to cause leakage of a phase changing material, and a product obtained by applying the body.
Provided is a microcapsule for latent heat storage materials including a metal core containing Zn and Al and a shell covering the metal core.
An object of the present invention is to provide a latent heat storage body which has a melting point of about 300 to 550° C. and is difficult to cause leakage of a phase changing material, and a product obtained by applying the body.
Provided is a microcapsule for latent heat storage materials including a metal core containing Zn and Al and a shell covering the metal core.
The shell of the microcapsule includes an oxide film containing Zn and O, and an oxide film containing Al and O adjacent to an inner side of the oxide film. In the microcapsule, a mass ratio of ZnAl2O4 is 4% or less. The mass ratio is determined by analyzing the microcapsule by an XRD (X-ray diffractometer) device and subjecting results to quantitative analysis using a RIR (Reference Integrity Ratio) method.
National University Corporation Hokkaido University (Japan)
Utsunomiya University (Japan)
Inventor
Ogasawara, Satoshi
Orikawa, Koji
Funato, Hirohito
Haruna, Junnosuke
Okazaki, Fumihiro
Abstract
Variation in inductance is reduced with a secondary-side coil substrate on which a plurality of wiring layers are superimposedly disposed, and a plurality of coils provided in the secondary-side coil substrate. On the wiring layer, coil patterns corresponding to parts of one circumferences of the coils are formed. On the wiring layer, coil patterns corresponding to remaining parts of the one circumferences of the coils are formed. The coil patterns, and the coil patterns that are provided on the different wiring layers are connected to each other via conduction points in a superimposition direction of the wiring layers, and the one circumferences of the respective coils are formed.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
NIDEK CO., LTD. (Japan)
Inventor
Saito, Michiyuki
Noda, Kousuke
Fukutsu, Kanae
Ishida, Susumu
Shiba, Ryosuke
Kumagai, Yoshiki
Abstract
A processor of a fundus image processing device acquires a fundus image 50 photographed by a fundus image photographing device. The processor acquires blood vessel images 60A and 60B that indicate at least one of an arteriole and a venule in the fundus image 50 by inputting the fundus image 50 into a mathematical model trained by a machine learning algorithm. The processor acquires a blood vessel area that is an area of at least one of the arteriole and the venule in the whole of the blood vessel images 60A and 60B.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Matsumoto, Shingo
Stewart, Neil
Uchio, Yoshiki
Abstract
15N nuclei, has a microfluidic device in which the precursor is guided in a magnetic shield such that the strength of the magnetic field acting on the precursor monotonically decreases from approximately 1 μT to zero magnetic field, and then the precursor is guided in the magnetic shield such that the strength of the magnetic field acting on the precursor monotonically increases from zero magnetic field to approximately 1 μT.
National University Corporation Hokkaido University (Japan)
Hitachi, Ltd. (Japan)
Inventor
Nakamura, Takahiro
Watanabe, Jyunichiro
Takemoto, Takashi
Tamakoshi, Akiko
Kimura, Takashi
Abstract
A health data processing system in which an arithmetic unit can gain access to a database storing basic data of residents, health data of residents, and social capital index measurement data is provided. The health data processing system includes: an individual health condition analysis part which analyzes an individual health condition being each resident's health condition with use of the health data; a regional health condition analysis part which analyzes a regional health condition being a health condition of residents who belong to a region with use of the health data; an SCI derivation part which derives a regional SCI being a social capital index for every region with use of the social capital index measurement data; and an individually providing information generation part which generates information contributing to residents' health with use of the individual health condition, the regional health condition, and the regional SCI.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G06F 16/25 - Integrating or interfacing systems involving database management systems
97.
NUCLEAR REACTION DETECTION APPARATUS, METHOD, AND PROGRAM
Nippon Telegraph and Telephone Corporation (Japan)
National University Corporation Hokkaido University (Japan)
National University Corporation Tokai National Higher Education and Research System (Japan)
Inventor
Iwashita, Hidenori
Funatsu, Gentaro
Furusaka, Michihiro
Kamiyama, Takashi
Sato, Hirotaka
Kiyanagi, Yoshiaki
Abstract
A nuclear reaction detection device includes an FPGA (Field Programmable Gate Array) 100 which is arranged in an environment in which particle radiation is incident, and includes a user circuit 101 configured to output a value different from that in a normal state, if an SEU (Single Event Upset) occurs in a semiconductor element included in the FPGA, and an SEF detection unit 210 which detects that an abnormal operation (SEF) has occurred in the user circuit based on the output value from the user circuit 101 of the FPGA 100.
Nippon Telegraph and Telephone Corporation (Japan)
National University Corporation Hokkaido University (Japan)
National University Corporation Tokai National Higher Education and Research System (Japan)
Inventor
Iwashita, Hidenori
Funatsu, Gentaro
Furusaka, Michihiro
Kamiyama, Takashi
Sato, Hirotaka
Kiyanagi, Yoshiaki
Abstract
A nuclear reaction detection device 100 includes a semiconductor memory 100 arranged in an environment in which radiation is incident, a position information storage unit 210 that stores spatial position information of a semiconductor element in the semiconductor memory 100, a bit position specifying unit 220 that detects that an SEU (Single Event Upset) has occurred in the semiconductor element included in the semiconductor memory 100, and specifies the semiconductor element in which the SEU has occurred, and a position calculating unit 230 that calculates a spatial position in which the SEU has occurred, based on the specified semiconductor element and the spatial position information.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
Inventor
Sato, Yusuke
Harashima, Hideyoshi
Tokeshi, Manabu
Maeki, Masatoshi
Abstract
The present invention addresses the problem of providing a lipid nanoparticle in which a nucleic acid, etc., required in genome editing is encapsulated and which can be produced by an alcohol dilution method using flow channels and contributes to high genome editing efficiency. The present invention pertains to a lipid nanoparticle which comprises a lipid component, a DNA nuclease, a guide RNA and a single-stranded oligonucleotide, wherein: the lipid component comprises a pH-sensitive cationic lipid, a neutral phospholipid and a polyalkylene glycol-modified lipid; the ratio of the pH-sensitive cationic lipid relative to the total lipids constituting the lipid nanoparticle is 30-50 mol %; the ratio of the neutral phospholipid relative to the total lipids constituting the lipid nanoparticle is 20-50 mol %; and the ratio of the polyalkylene glycol-modified lipid relative to the total lipids constituting the lipid nanoparticle is 1-4 mol %.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
100.
SINTERED BODY, METHOD FOR PRODUCING SAME, AND DIELECTRIC COMPOSITION
National University Corporation Hokkaido University (Japan)
Murata Manufacturing Co., Ltd. (Japan)
Inventor
Masubuchi, Yuji
Hosono, Akira
Kikkawa, Shinichi
Inoguchi, Masashi
Abstract
A sintered body containing polycrystalline grains of a metal oxynitride containing at least two metal elements, wherein Ba and at least one metal element of a crystal phase of the sintered body are contained in a triple point that is not a void between the polycrystalline grains. A method for producing the sintered body includes sintering a mixture of at least a metal oxynitride as a main component and a sintering aid containing cyanamide in an atmosphere containing nitrogen or a rare gas or in a reduced-pressure atmosphere of 10 Pa or less while applying a mechanical pressure with a retention time at a maximum heating temperature during the sintering set to 1 minute to 10 minutes.
C04B 35/58 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on borides, nitrides or silicides